Key Inclusion Criteria:  Provide written, informed consent to participate in the study and follow the study procedures Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1 Measurable disease per RECIST 1.1 criteria Patients must have histologically confirmed metastatic melanoma with measurable, stage IV disease per American Joint Committee on Cancer (AJCC) staging system In patients with a single RECIST measurable lesion, the lesion must be a non-cutaneous lesion. Fresh biopsy Treatment-naive patients (i.e., no prior systemic anticancer therapy for unresectable or metastatic melanoma).  Key Exclusion Criteria:  Patients who have an active, known or suspected autoimmune disease Patients must not have received prior IL-2 therapy Prior treatment with an anti PD-1, anti PD-L1, or anti cytotoxic T lymphocyte associated protein 4 (anti CTLA-4) antibody, agents that target IL-2, or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways Need for >2 antihypertensive medications for hypertension management  Other protocol-defined inclusion/exclusion criteria apply